G1 Therapeutics/GTHX

$3.73

12.34%
-
1D1W1MYTD1YMAX

About G1 Therapeutics

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy designed to help and protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lung cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. Its Rintodestrant, is an oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2 (HER2)-breast cancer.

Ticker

GTHX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Bailey

Employees

100

Headquarters

Research triangle park, United States

G1 Therapeutics Metrics

BasicAdvanced
$194.7M
Market cap
-
P/E ratio
-$0.95
EPS
1.70
Beta
-
Dividend rate

What the Analysts think about G1 Therapeutics

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 4 analysts.
127.88% upside
High $12.00
Low $5.00
$3.73
Current price
$8.50
Average price target

G1 Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-72.97% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$14.8M
20.33%
Net income
$-10.8M
-40.66%
Profit margin
-72.97%
-50.68%

G1 Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 23.69%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.53
$0.14
-$0.35
-$0.21
-
Expected
-$0.64
-$0.22
-$0.33
-$0.28
-$0.22
Surprise
-17.19%
-164%
6.38%
-23.69%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell G1 Therapeutics stock

Buy or sell G1 Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing